The U.S. Food and Drug Administration (FDA) has approved Alembic Pharmaceuticals’ generic Betamethasone Valerate Foam, 0.12% for moderate-to-severe psoriasis of the scalp
The Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product Luxiq Foam, 0.12% from Norvium Bioscience, LLC.
Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
Alembic now has a total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from FDA, according to a company press release.
